AlphaStocks
7.5
Strong Buy

Amphastar Pharmaceuticals, Inc. (AMPH)

As of Sep 20, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) scores 7.5/10 on AlphaStocks' five-model composite, #4 of 168 Health Care stocks.

Health Care / Pharmaceuticals

S&P SmallCap 600

$23.60

Above average across most dimensions. A solid candidate.

Strong Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#4out of 168 in Health Care

Is Amphastar Pharmaceuticals, Inc. a Good Investment in 2026?

Amphastar Pharmaceuticals, Inc. (AMPH) scores 7.5 out of 10 on AlphaStocks' composite model, earning a Strong Buy rating. The Piotroski model rates Amphastar Pharmaceuticals, Inc. as Attractive (6/9). The Greenblatt Magic Formula model is the least favorable, rating it Attractive. Amphastar Pharmaceuticals, Inc. ranks #4 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

Market Cap1B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Attractive

Business quality & competitive moat

Graham

Attractive

26% below fair value

Lynch

Attractive

Growth rate vs price (PEG)

Greenblatt

Attractive

Earnings yield 10.4% · ROC 18%

Frequently Asked Questions

Is Amphastar Pharmaceuticals, Inc. (AMPH) a good investment?
As of Sep 20, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) scores 7.5/10 on AlphaStocks' five-model composite, #4 of 168 Health Care stocks. That score is above average across most investment dimensions. Currently unprofitable — fair value estimate not available.
What is Amphastar Pharmaceuticals, Inc.'s Piotroski F-Score?
Amphastar Pharmaceuticals, Inc.'s Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is AMPH overvalued or undervalued?
A precise fair value estimate is not available for AMPH. Currently unprofitable — fair value estimate not available.
How does AMPH compare to other Health Care stocks?
Amphastar Pharmaceuticals, Inc. ranks #4 out of 168 stocks in the Health Care sector, placing it in the top 2% of its sector by composite score. This is a strong position relative to sector peers.
What do investment models say about AMPH?
AlphaStocks evaluates AMPH using five proven investment models. Piotroski: Attractive; Buffett: Attractive; Graham: Attractive; Lynch: Attractive; Greenblatt Magic Formula: Attractive. These models are combined into a single composite score of 7.5/10.

Similar Stocks

LLYACADAMRX

Compare AMPH with

AMPH vs LLYACAD vs AMPHAMPH vs AMRX

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer